Dr. Michael Dennis, CAS Chief Science Officer, noted that “Expanding our collaboration with Aptean through the Chemical Modification module presents an exciting opportunity to further our mission of ...
CRISPR-Cas13, a powerful RNA-targeting technology is gaining increasing attention as a next-generation gene therapy platform due to its precision and reduced side effects. Utilizing this system, ...
Researchers have discovered a mechanism in DNA that regulates how disease-causing mutations are inherited. The team identified two enzymes that regulate a chemical modification, 6mA, in mitochondrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback